NCT06245408: An ongoing trial by Amgen
This trial is ongoing. It must report results 11 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06245408 |
|---|---|
| Title | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-Severe Symptom State (HZNP-DAZ-303) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 8, 2024 |
| Completion date | Oct. 22, 2026 |
| Required reporting date | Oct. 22, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 3, 2026 |
| Days late | None |